Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accumulated Expenses (2016 - 2026)

Myriad Genetics has reported Accumulated Expenses over the past 16 years, most recently at $96.9 million for Q4 2025.

  • Quarterly Accumulated Expenses fell 18.57% to $96.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.9 million through Dec 2025, down 18.57% year-over-year, with the annual reading at $96.9 million for FY2025, 18.57% down from the prior year.
  • Accumulated Expenses was $96.9 million for Q4 2025 at Myriad Genetics, down from $108.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $164.3 million in Q2 2023 and troughed at $83.1 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $104.4 million (2025), against an average of $113.0 million.
  • Year-over-year, Accumulated Expenses skyrocketed 149.54% in 2021 and then plummeted 47.73% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $161.7 million in 2021, then plummeted by 41.68% to $94.3 million in 2022, then grew by 20.78% to $113.9 million in 2023, then grew by 4.48% to $119.0 million in 2024, then dropped by 18.57% to $96.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Accumulated Expenses are $96.9 million (Q4 2025), $108.3 million (Q3 2025), and $100.6 million (Q2 2025).